Plenary and opening welcome to Psychedelic Science 2017 - Rick Doblin, PhD, Amanda Feilding, and Beatriz Labate, PhD.
01:11:17 min
CLEAR ALL
Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization.
1
Dr. Robin Carhart-Harris, of the Neuropsychopharmacology Unit, Imperial College London, discusses research on Psilocybin and how psychedelics could be used in therapy to help with depression, addiction, and other problems of rigid thought patterns.
Robin has been conducting pioneering brain imaging studies of psychedelic drugs. Most recently, he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression, and his talk looks at how these drugs can be used in treatment.
Psychedelics afford a unique opportunity to expand our understanding of consciousness and its altered states, to develop techniques for enhancing consciousness, and to uncover new avenues of treatment and improved therapeutic techniques.
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.